Scotland Backs Bayer's Xofigo In Prostate Cancer Before England
This article was originally published in Scrip
The Scottish Medicines Consortium (SMC) has published advice accepting six new medicines for use in NHS Scotland, three of which have yet to receive final vetting from NICE – the HTA body for England and Wales.
You may also be interested in...
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.
Acasti’s omega-3 candidate drug CaPre missed the primary endpoint in TRILOGY-1 due to an unexplained high placebo effect, as AstraZeneca said its STRENGTH study was unlikely to show a treatment benefit.
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.